Cargando…
Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways
BACKGROUND: Acquired pemetrexed resistance leads to treatment interruption in patients with malignant pleural mesothelioma (MPM). Insulin-like growth factor-I receptor (IGF-1R) inhibitor is a candidate for treating pemetrexed-naïve MPM. However, the efficacy of cytotoxic and targeted drugs in acquir...
Autores principales: | Sun, Rong, Tanino, Ryosuke, Tong, Xuexia, Haque, Eshat Fahmida, Amano, Yoshihiro, Isobe, Takeshi, Tsubata, Yukari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073748/ https://www.ncbi.nlm.nih.gov/pubmed/35529797 http://dx.doi.org/10.21037/tlcr-21-765 |
Ejemplares similares
-
Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer
por: Tanino, Ryosuke, et al.
Publicado: (2018) -
Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
por: Okimoto, Tamio, et al.
Publicado: (2020) -
Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
por: Tsubata, Yukari, et al.
Publicado: (2021) -
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
por: Tong, Xuexia, et al.
Publicado: (2019) -
Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)